← Back to headlines

Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate

GlobeNewswire·Feb 24

This story is reported by GlobeNewswire. Read what other outlets are saying below, then open the original report for full details.

View original report at GlobeNewswire ↗
Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate · NabkaNews